ImmuCell Corporation Reports 28.4% Increase in Product Sales for Q1 2026

ImmuCell Corporation reported a significant increase in financial performance for the first quarter of 2026, with product sales reaching $10.4 million, a 28.4% increase from $8.1 million in the same period last year. The company's gross profit also rose to $4.7 million, up 38.9% from $3.4 million in the prior year. This growth was attributed to higher sales volumes of its First Defense® product line, which accounted for 99.5% of total sales, alongside price increases across most product lines. The net income for the quarter was $1.9 million, compared to $1.4 million in the previous year, resulting in a basic net income per share of $0.21, up from $0.16.

In terms of operational changes, ImmuCell's total assets increased to $44.1 million as of March 31, 2026, compared to $42.5 million at the end of 2025. The company also reported a notable increase in cash and cash equivalents, which rose by 79% to $6.8 million. The increase in cash flow was primarily driven by improved net income and more efficient management of working capital, particularly in inventory and accounts receivable. The company’s net cash provided by operating activities surged to $3.6 million, a significant increase from $1.6 million in the same quarter of the previous year.

Strategically, ImmuCell has made adjustments to its operational focus, particularly regarding its Re-Tain® product line. The company has decided to cease efforts to obtain FDA approval for Re-Tain® and instead plans to repurpose the associated manufacturing facility for First Defense® products. This decision has led to a reassessment of the useful lives of certain manufacturing equipment, resulting in a decrease in depreciation expense and an increase in operating income. Additionally, the company has made changes in its executive team, with new employment agreements for key positions, including the President and CEO, which may impact future performance.

The company’s sales and marketing expenses increased by 43.9% to $1.2 million, reflecting higher wages and promotional activities as the company ramped up its commercial efforts following a period of tight product supply. Administrative expenses also rose significantly, primarily due to increased executive compensation. Despite these increases, product development expenses decreased by 58% to $0.3 million, as costs associated with the Re-Tain® facility were shifted to cost of goods sold.

Looking ahead, ImmuCell remains optimistic about its growth trajectory, particularly with the anticipated demand for its First Defense® product line. The company is focused on enhancing its production capacity and expanding its market presence, especially in the domestic market, where sales have shown strong growth. However, management acknowledges potential risks, including market conditions and operational challenges, which could impact future performance. The company plans to continue monitoring these factors closely as it executes its strategic initiatives.